PMID- 21558130
OWN - NLM
STAT- MEDLINE
DCOM- 20110825
LR  - 20131121
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 168
IP  - 20
DP  - 2011 May 21
TI  - Evaluation of a human generic formulation of ciclosporin in the treatment of 
      canine atopic dermatitis with in vitro assessment of the functional capacity of 
      phagocytic cells.
PG  - 537
LID - 10.1136/vr.c7365 [doi]
AB  - To compare the efficacy, tolerability and safety of a generic formulation of 
      ciclosporin for human beings with prednisone in the treatment of canine atopic 
      dermatitis), human generic ciclosporin A (hgCsA) (5 mg/kg daily) and prednisone 
      (1 mg/kg daily for seven days, followed by 1 mg/kg every second day) were 
      administered to 13 and seven dogs with atopic dermatitis, respectively, for 42 
      days. Skin changes were assessed using a modified canine atopic dermatitis extent 
      and severity index (mCADESI-01) and a pruritus intensity scale system. The in 
      vitro functional capacity of phagocytic cells was assessed using the tetrazolium 
      reductase activity and zymosan-stimulated tetrazolium reductase activity tests, 
      as well as measurements of the percentage phagocytic activity and the ingestion 
      capacity of phagocytic cells. Haematological and biochemical parameters were also 
      monitored. There was a greater than or equal to 50 per cent reduction from the 
      baseline in mCADESI-01 scores in 84.6 and 100 per cent of dogs, and a greater 
      than or equal to 50 per cent reduction from the baseline in pruritus scores in 
      76.9 and 85.7 per cent of dogs, treated with hgCsA and prednisone, respectively. 
      No important adverse physical, haematological or biochemical effects occurred 
      with either drug and no statistically significant changes were detected in any of 
      the four tests assessing the functional activity of phagocytes. The generic 
      formulation of ciclosporin was effective in reducing the severity of physical 
      signs of canine atopic dermatitis and was well tolerated.
FAU - Kovalik, M
AU  - Kovalik M
AD  - University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovak 
      Republic. mkovalikos@yahoo.com
FAU - Taszkun, I
AU  - Taszkun I
FAU - Pomorski, Z
AU  - Pomorski Z
FAU - Kozak, M
AU  - Kozak M
FAU - Pomorska, D
AU  - Pomorska D
FAU - Szczepanik, M
AU  - Szczepanik M
FAU - Wilkolek, P
AU  - Wilkolek P
FAU - Palenik, L
AU  - Palenik L
FAU - Shaw, D J
AU  - Shaw DJ
FAU - van den Broek, A H M
AU  - van den Broek AH
FAU - Thoday, K L
AU  - Thoday KL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110509
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
RN  - 0 (Dermatologic Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - VB0R961HZT (Prednisone)
SB  - IM
CIN - Vet Rec. 2011 May 21;168(20):533-4. PMID: 21602409
MH  - Animals
MH  - Cyclosporine/*therapeutic use
MH  - Dermatitis, Atopic/drug therapy/pathology/*veterinary
MH  - Dermatologic Agents/*therapeutic use
MH  - Dog Diseases/*drug therapy/pathology
MH  - Dogs
MH  - Female
MH  - Humans
MH  - Male
MH  - Phagocytes/drug effects/*physiology
MH  - Pilot Projects
MH  - Prednisone/therapeutic use
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2011/05/12 06:00
MHDA- 2011/08/27 06:00
CRDT- 2011/05/12 06:00
PHST- 2011/05/12 06:00 [entrez]
PHST- 2011/05/12 06:00 [pubmed]
PHST- 2011/08/27 06:00 [medline]
AID - vr.c7365 [pii]
AID - 10.1136/vr.c7365 [doi]
PST - ppublish
SO  - Vet Rec. 2011 May 21;168(20):537. doi: 10.1136/vr.c7365. Epub 2011 May 9.